Day: May 6, 2020

Styret i Havila Shipping ASA kaller inn til Ordinær GeneralforsamlingGeneralforsamlingen holdes 28. mai 2020 kl 14:00 i Havilahuset, Fosnavåg, NorgeInnkallingen sendes aksjonærene per post eller e-post via VPS.Kontakter:Adm dir Njål Sævik, +47 909 35 722Finansdir Arne Johan Dale, +47 909 87 706Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12Vedlegg2020GM

As a comprehensive consulting and managed services provider, Xceedance collaborates with insurers, reinsurers, MGAs, and brokers worldwide to optimize operations, apply intelligent technologies, increase analytic capabilities, and boost profitability. Xemplar Insights complements Xceedance offerings with innovative digital solutions using smartphone, cloud, and data technologies. With Xemplar’s mobile platforms and proprietary smartphone-based telematics for personal and commercial lines insurers, Xceedance will augment its technology capabilities for insurance organizations looking to launch and service user-based insurance (UBI) products. The Xemplar-Xceedance partnership also delivers modern, insurer-branded mobile apps with rich features for policy and claims services. “We are constantly looking to strengthen our leading-edge platforms...

Date: 6 May 2020Release: Before opening of EuronextPlease open the following link to read the full report including annexes:AttachmentFull press release

TORONTO, May 06, 2020 (GLOBE NEWSWIRE) — Galantas Gold Corporation (the “Company“) (TSXV:GAL) (AIM:GAL), the AIM and TSXV quoted gold producer and explorer announces that it has filed a Technical Report regarding underground exploration on its 100% owned gold mine near Omagh, Northern Ireland.As outlined on April 24, 2020, this technical report details a recent probe drilling campaign carried out underground at the Omagh mine. The results of the campaign, combined with detailed mapping of the exposed mineralisation underground suggest zones of higher width of mineralisation within the vein, linking adjacent levels. The results support a model that such zonal mineralisation may continue at depth, with enhanced exploration potential for targeting gold resources on site and within the Company’s license area. The technical...

Wolters Kluwer First-Quarter 2020 Trading UpdateMay 6, 2020 – Wolters Kluwer, a global leader in professional information, software solutions, and services, today releases an update on first-quarter 2020 trading and the impact of COVID-19.Highlights2020 guidance suspended due to uncertainty caused by the impact of COVID-19.Recurring revenues (approximately 80% of annual revenues) expected to show resilience.Non-recurring revenues expected to see weaker trends in current market conditions.First-quarter revenues up 3% in constant currencies and up 4% organically.Recurring revenues (82%) rose 5% while non-recurring revenues declined 2% organically.Digital & services revenues (93%) grew 5% while print revenues declined 13% organically.First-quarter adjusted operating profit margin increased by 110 basis points.First-quarter adjusted free...

Kiadis Pharma announces U.S. FDA approval to start NK-REALM Phase 2 clinical trial for natural killer (NK) cell therapy produced with PM21FDA approval of Investigational New Drug (IND) application supports the Company’s planned NK-REALM Phase 2 study which will evaluate K-NK002 in 63 patients with blood cancer undergoing a haploidentical hematopoietic stem cell transplant (HSCT)Amsterdam, The Netherlands, May 6, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to start its NK-REALM phase 2 clinical trial, which the Company submitted through an investigational new drug (IND) application in April 2020. Kiadis is developing K-NK002 as an adjunctive therapy...

                                              Kiadis Pharma kondigt goedkeuring van Amerikaanse FDA aan voor start van NK-REALM Fase 2-klinische studie voor met PM21 geproduceerde natural killer (NK)-celtherapieFDA-goedkeuring van Investigational New Drug ondersteunt de geplande NK-REALM Fase 2-studie waarin K-NK002 geëvalueerd wordt bij 63 patiënten met bloedkanker die een haplo-identieke hematopoïetische stamceltransplantatie (HSCT) ondergaanDit persbericht vormt een vertaling van het gelijktijdig gepubliceerde Engelstalige persbericht. Bij eventuele verschillen is de tekst van het Engelstalige persbericht altijd bepalend.Amsterdam, 6 mei 2020 – Kiadis Pharma N.V. (‘Kiadis Pharma’ of de ‘Onderneming’) (Euronext Amsterdam en Brussel: KDS), een biofarmaceutisch bedrijf gericht op de klinische fase, heeft vandaag aangekondigd dat het van...

COPENHAGEN, Denmark, May 6, 2020 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced that it has entered into an exclusive head of terms agreement with AdaptVac, a joint venture established by ExpreS2ion Biotechnologies and NextGen Vaccines spun out of the University of Copenhagen, to license AdaptVac’s proprietary capsid virus like particle (VLP) based SARS-CoV-2 subunit vaccine. The parties seek to enter into the final license agreement within the next two months.AdaptVac is a member of the international PREVENT-nCoV consortium that includes several European universities and earlier this year received an EU Horizon grant to rapidly advance AdaptVac’s vaccine candidate against COVID-19 into the clinic. The members of the consortium hold preclinical and clinically validated experience from working with similar coronaviruses...

KØBENHAVN, Danmark, 6. maj 2020 – Bavarian Nordic A/S (OMX: BAVA) offentliggør i dag, at selskabet har indgået en eksklusiv, foreløbig licensaftale med AdaptVac, som er et joint venture etableret af ExpreS2ion Biotechnologies og NextGen Vaccines – et spin-out fra Københavns Universitet, vedrørende AdaptVacs capsid virus like particle (VLP)-baserede SARS-CoV-2 subunit vaccine. Parterne forventer at indgå en endelig licensaftale inden for de næste to måneder.AdaptVac er medlem af det internationale PREVENT-nCoV-konsortium, der inkluderer flere europæiske universiteter, og som tidligere i år modtog en bevilling fra EU’s rammeprogram for forskning og innovation, Horisont 2020, med henblik på at bringe udviklingen af AdaptVac’s vaccinekandidat mod COVID-19 videre ind i kliniske forsøg. Medlemmerne af konsortiet har præklinisk...

ICG Enterprise Trust Plc: Notification of Transactions of Persons Discharging Managerial ResponsibilitiesICG ENTERPRISE TRUST PLC (the “Company”)6 May 2020Notification of Transactions of Persons Discharging Managerial ResponsibilitiesThis announcement is made pursuant to Article 19 of the Market Abuse Regulation.The Company wishes to announce that it received notification on 5 May 2020 that Sandra Pajarola, a Non-Executive Director, bought a 5,000 ordinary shares in the Company at an average price of 700 pence per share.As a result of this transaction Sandra Pajarola and her connected persons hold a total of 25,000 ordinary shares, being 0.03% of the ordinary share capital of the Company (excluding treasury shares).ContactsInvestor Enquiries:Ian StanlakeHead of Investor Relations+44 (0) 20 3201 7700Media Enquiries:Vikki KosmalskaAssociate...